Suppr超能文献

作为两个预后标志物的FBLN - 4和BCRP基因在乳腺癌组织中表达下调。

FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.

作者信息

Motalebzadeh Jamshid, Mahjoubi Frouzandeh, Nafissi Nahid, Hashemian Maria, Taheri Mohsen, Hosseinpour Younes

机构信息

Department of Clinical Genetic, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Iran University of Medical Science, RasoleAkram Hospital, Tehran, Iran.

出版信息

Cancer Biomark. 2017;19(1):51-55. doi: 10.3233/CBM-160335.

Abstract

BACKGROUND

Fibulin-4 (FBLN-4) is an extracellular glycoprotein that is upregulated in some cancer and is khown as prognostic marker in ovarian and cervical cancer. Breast cancer resistance protein (BCRP) is an ATP-binding cassette transporter that facilitates the efflux of various anticancer drugs from the cell and cause MDR phenotype in breast tumors. Many studies are available that indicat overexpression of BCRP gene in breast cancer.

OBJECTIVE

In the present study we aimed to analyze the expression level of FBLN-4 and BCRP in Iranian breast cancer patients.

METHODS

We collected 40 samples of breast cancer and normal tissue from Tehran Khatam-al-Anbia hospital. To analyze the gene expression by using Real Time RT-PCR FBLN-4 and BCRP gene expression level were measured and then the association of gene expression with breast cancer were determined.

RESULTS

Surprisingly the expression level of FBLN-4 and BCRP genes were downregulated in tumor tissues compared to adjacent normal tissues. Comparison of the gene expression and clinico-pathology reports indicate FBLN-4 gene expression was associated with breast cancer histological grade. We found no correlation between the expressions of BCRP gene with any clinico-pathological characters.

CONCLUSION

Interestingly and in contrast with our expectation, we found that the expression level of FBLN-4 and BCRP were downregulated in tumor compared to adjacent normal tissues. FBLN-4 was associated with grade histology and therefore can be considered as a potential prognostic biomarker.

摘要

背景

纤连蛋白-4(FBLN-4)是一种细胞外糖蛋白,在某些癌症中上调,是卵巢癌和宫颈癌的预后标志物。乳腺癌耐药蛋白(BCRP)是一种ATP结合盒转运蛋白,可促进各种抗癌药物从细胞中流出,并在乳腺肿瘤中导致多药耐药(MDR)表型。有许多研究表明BCRP基因在乳腺癌中过表达。

目的

在本研究中,我们旨在分析伊朗乳腺癌患者中FBLN-4和BCRP的表达水平。

方法

我们从德黑兰哈塔姆-安比亚医院收集了40份乳腺癌和正常组织样本。通过实时逆转录聚合酶链反应(Real Time RT-PCR)分析基因表达,测量FBLN-4和BCRP基因表达水平,然后确定基因表达与乳腺癌的相关性。

结果

令人惊讶的是,与相邻正常组织相比,肿瘤组织中FBLN-4和BCRP基因的表达水平下调。基因表达与临床病理报告的比较表明,FBLN-4基因表达与乳腺癌组织学分级相关。我们发现BCRP基因的表达与任何临床病理特征之间均无相关性。

结论

有趣的是,与我们的预期相反,我们发现与相邻正常组织相比,肿瘤中FBLN-4和BCRP的表达水平下调。FBLN-4与组织学分级相关,因此可被视为一种潜在的预后生物标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验